Science Explorer Back to mapMap
Discussion
Institution · National Marrow Donor Program

Most cited papers from National Marrow Donor Program

National Marrow Donor Program

What are the most cited papers from National Marrow Donor Program?

The most cited paper from National Marrow Donor Program is "Nomenclature for Factors of the HLA System, 2026" (Steven G.E. Marsh et al., 2010), with 4,206 citations. Next come "High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation" (1,261) and "HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry" (1,117).

Showing 50 of 59 papers. Every paper with more than 212 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Nomenclature for Factors of the HLA System, 2026 Steven G.E. Marsh et al. · Tissue Antigens Open access 17 Mar 2010 4,206
2 High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation Stephanie J. Lee, John P. Klein, Michael D. Haagenson et al. · Blood Open access 4 Sep 2007 1,261
3 HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry Loren A. Gragert, Mary Eapen, Eric Williams et al. · New England Journal of Medicine Open access 23 Jul 2014 1,117
4 Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors Claudio Anasetti et al. · New England Journal of Medicine Open access 18 Oct 2012 919
5 Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation Robert Coleman Lindsley, Wael Saber, Brenton G. Mar et al. · New England Journal of Medicine Open access 8 Feb 2017 788
6 Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group Jamie K. Waselenko, Thomas J. MacVittie, William F. Blakely et al. · Annals of Internal Medicine 15 Jun 2004 770
7 Current Use of and Trends in Hematopoietic Cell Transplantation in the United States Anita D’Souza et al. · Transplantation and Cellular Therapy Open access 10 May 2020 722
8 Risk factors for acute GVHD and survival after hematopoietic cell transplantation Madan Jagasia et al. · Blood Open access 19 Oct 2011 717
9 Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age Craig Kollman, Craig W. S. Howe, Claudio Anasetti et al. · Blood Open access Oct 2001 707
10 Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue Laura S. Connelly‐Smith, Caroline Raasch Alquist, Nicole A. Aqui et al. · Journal of Clinical Apheresis Apr 2023 661
11 A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion- associated CMV infection after marrow transplant [see comments] RA Bowden, SJ Slichter, Merlyn H Sayers et al. · Blood Nov 1995 635
12 Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia Sarah Cooley, Daniel Jordan Weisdorf, Lisbeth A. Guethlein et al. · Blood Open access 25 Jun 2010 593
13 The Shaping of Modern Human Immune Systems by Multiregional Admixture with Archaic Humans Laurent Abi‐Rached et al. · Science Open access 25 Aug 2011 565
14 Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation Navneet S. Majhail, James Douglas Rizzo sup sup, Stephanie Joi Lee sup sup et al. · Revista Brasileira de Hematologia e Hemoterapia Open access 2012 509
15 Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma Paul Gerard Guy Richardson et al. · New England Journal of Medicine Open access 5 Jun 2022 494
16 Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade Jayne S. Sutherland, Gabrielle L. Goldberg, Maree V. Hammett et al. · The Journal of Immunology Open access Aug 2005 489
17 Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation John R. Wingard, Shelly L. Carter, Thomas J. Walsh et al. · Blood Open access 8 Sep 2010 484
18 High-resolution HLA alleles and haplotypes in the United States population Martin J. Maiers, Loren A. Gragert, William Klitz · Human Immunology 25 May 2007 473
19 Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease Christopher Simon Hourigan et al. · Journal of Clinical Oncology Open access 20 Dec 2019 456
20 One million haemopoietic stem-cell transplants: a retrospective observational study Alois A. Gratwohl et al. · The Lancet Haematology 26 Feb 2015 443
21 Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research Sally Arai et al. · Transplantation and Cellular Therapy Open access 30 Oct 2014 443
22 Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry Loren A. Gragert, Abeer S. Madbouly, John L. Freeman et al. · Human Immunology Open access 25 Jun 2013 440
23 Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation Navneet S. Majhail, Stephanie H. Farnia, Paul A. Carpenter et al. · Transplantation and Cellular Therapy Open access 8 Aug 2015 413
24 Placental and/or Umbilical Cord Blood: An Alternative Source of Hematopoietic Stem Cells for Transplantation Mitchell Stuart Cairo, John E. Wagner · Blood 15 Dec 1997 394
25 Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial Theodore Willis Laetsch et al. · Journal of Clinical Oncology Open access 18 Nov 2022 382
26 The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy Craig Kollman et al. · Blood Open access 2 Nov 2015 367
27 Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study Akshay Sharma, Neel Sanjivbhai Bhatt, Andrew St. Martin et al. · The Lancet Haematology Open access 19 Jan 2021 360
28 Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study Katharina L. Fleischhauer, Bronwen E. Shaw, Theodore A. Gooley et al. · The Lancet Oncology Open access 14 Feb 2012 359
29 Mature CD10+ and immature CD10− neutrophils present in G-CSF–treated donors display opposite effects on T cells Olivia Marini et al. · Blood Open access 4 Jan 2017 357
30 The HLA dictionary 2008: a summary of HLA‐A, ‐B, ‐C, ‐DRB1/3/4/5, and ‐DQB1 alleles and their association with serologically defined HLA‐A, ‐B, ‐C, ‐DR, and ‐DQ antigens Rhonda F. Holdsworth, Carolyn Katovich Hurley, Steven G. E. Marsh et al. · Tissue Antigens Open access 6 Jan 2009 356
31 Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies Robert J. Soiffer, Jennifer G. Le‐Rademacher, Vincent T. Ho et al. · Blood Open access 5 Apr 2011 354
32 Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas Gregory K. Friedman et al. · New England Journal of Medicine Open access 10 Apr 2021 332
33 Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR Jason G. Dehn, Stephen R. Spellman, Carolyn Katovich Hurley et al. · Blood Open access 10 Jul 2019 325
34 Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey Dietger Niederwieser et al. · Bone Marrow Transplantation Open access 22 Feb 2016 312
35 Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT Jeffrey S. Miller, Sarah Cooley, Peter R Parham et al. · Blood Open access 23 Feb 2007 286
36 X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production Orchidée Filipe‐Santos et al. · The Journal of Experimental Medicine Open access 3 Jul 2006 284
37 Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation Joseph Pidala et al. · Blood Open access 27 Aug 2014 283
38 The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure Stephen R. Spellman, Robert A. Bray, Sandra Rosen‐Bronson et al. · Blood Open access 21 Jan 2010 278
39 Progress toward an efficient panel of SNPs for ancestry inference Kenneth K. Kídd, William C. Speed, ANDREW J. PAKSTIS et al. · Forensic Science International Genetics Open access 15 Jan 2014 276
40 Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program Michael A. Pulsipher, Pintip Chitphakdithai, J. Philip Miller et al. · Blood Open access 4 Feb 2009 271
41 Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy Mary Eapen et al. · Blood Open access 19 Oct 2013 265
42 CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets Michelle Gleason, Julie A. Ross, Erica Dahl Warlick et al. · Blood Open access 21 Mar 2014 262
43 Prevalence of Hematopoietic Cell Transplant Survivors in the United States Navneet S. Majhail, Li Tao, Christopher Bredeson et al. · Transplantation and Cellular Therapy Open access 30 Jul 2013 256
44 IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial Linda J. Burns, Daniel Jordan Weisdorf, Todd E. DeFor et al. · Bone Marrow Transplantation Jul 2003 251
45 One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors Dietger W. Niederwieser et al. · Haematologica Open access 12 Aug 2021 250
46 Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors Theresa Hahn, Philip L. McCarthy, Anna M. Hassebroek et al. · Journal of Clinical Oncology Open access 29 May 2013 250
47 The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry Sherif Shafik Farag, Andrea Paolo Bacigalupo, Mary Eapen et al. · Transplantation and Cellular Therapy Open access 24 Jul 2006 243
48 Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation N S Majhail, J D Rizzo, S J Lee et al. · Bone Marrow Transplantation Open access Mar 2012 242
49 Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program Philip B. McGlave, Xiao Ou Shu, Wanqing Wen et al. · Blood Apr 2000 236
50 Common and well‐documented HLA alleles: 2012 update to the CWD catalogue Steven J. Mack et al. · Tissue Antigens Open access 20 Mar 2013 235

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.